BD-1008

CAT: 0804-HY-135608-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-135608-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BD-1008 is a nonselective σ receptor antagonist with Kis against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 has an extremely low affinity for the D2 receptor (Ki = 1112 nM) and dopamine transporter (DAT) (Ki > 10,000 nM) . BD-1008 significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 blocks the self-administration behavior of σ agonists.BD-1008 can be used for the study of addiction therapy that target the σ receptor[1][2][3].
CAS Number
[138356-08-8]
UNSPSC
12352005
Target
Sigma Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/bd-1008.html
Purity
98.41
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
CN(CCC1=CC=C(Cl)C(Cl)=C1)CCN2CCCC2
Molecular Formula
C15H22Cl2N2
Molecular Weight
301.25
References & Citations
[1]Staelens L, et al. In vivo evaluation of [ (123) I]-3- (4-iodobenzyl) -1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studies. Nucl Med Biol. 2005 Apr;32 (3) :293-9. |[2]Garcés-Ramírez L, et al. Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry. 2011 Feb 1;69 (3) :208-17.|[3]Hiranita T, et al. Stimulants as specific inducers of dopamine-independent σ agonist self-administration in rats. J Pharmacol Exp Ther. 2013 Oct;347 (1) :20-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Sigma 1 Receptor; Sigma 2 Receptor